Retatrutide before Phase 3: what the trials show so far

Where the story stands

The 2023 NEJM publication of TRIUMPH-1 Phase 2 results in obesity (Jastreboff et al.) reported placebo-adjusted weight loss of approximately 22% at 48 weeks at the 12 mg dose. Not all participants reached steady-state at 48 weeks — many were still losing weight at the trial's end — making the published number likely an underestimate of the asymptotic ceiling.

For reference, the comparable Phase 3 numbers for currently-approved agents are tirzepatide ~21% (SURMOUNT-1, 72 weeks) and semaglutide 2.4 mg ~15% (STEP 1, 68 weeks). The Phase 2 retatrutide data, while technically not directly comparable due to different durations and trial designs, suggests retatrutide will reset the ceiling on what pharmacologic obesity therapy can achieve.

The triple-receptor design

Retatrutide activates three incretin-related receptors: GLP-1 (the established appetite-suppression and glucose-control arm), GIP (the dual-agonist arm tirzepatide proved valuable), and glucagon (a novel third arm contributing energy expenditure). The glucagon component is what differentiates retatrutide from tirzepatide and is the most distinctive part of the molecular story.

Glucagon agonism alone would raise glucose, which would be unhelpful in a metabolic therapy. Retatrutide's design balances glucagon's energy-expenditure benefit against GLP-1's glucose-lowering effect, with engineered receptor affinity ratios producing net glycemic benefit while retaining the metabolic-rate effect.

What's not yet answered

The TRIUMPH Phase 3 program is the gating event for retatrutide's clinical positioning. Open questions include:

• Phase 3 weight-loss durability — does the magnitude shown in Phase 2 hold up across the much larger Phase 3 populations and longer follow-up?
• Cardiovascular outcomes — TRIUMPH-OUTCOMES is the dedicated CV trial; results will determine whether retatrutide joins semaglutide and (anticipated) tirzepatide on the CV outcomes ledger.
• MASH outcomes — TRIUMPH-MASH is dedicated to liver disease; positive results would extend the indication landscape considerably.
• Heart rate effects — the glucagon arm produces modest heart-rate elevation; the cardiovascular significance over multi-year exposure is part of what TRIUMPH-OUTCOMES will determine.
• Body composition — DEXA substudies will clarify how lean-mass loss compares to tirzepatide and semaglutide at the larger weight-loss magnitudes retatrutide produces.

What it would take to displace tirzepatide

For retatrutide to become the new clinical reference, three things would need to be true: Phase 3 weight loss >25% in a typical obesity population, cardiovascular outcomes at least non-inferior to semaglutide's SELECT result, and a tolerability profile not meaningfully worse than tirzepatide. The Phase 2 data suggests this is plausible. The Phase 3 program is what determines whether it becomes empirically true.

The MariTide question

Worth noting alongside retatrutide: Amgen's MariTide (maridebart cafraglutide), a GLP-1 agonist plus GIP receptor antagonist with monthly dosing. If MariTide's Phase 3 confirms the antagonist hypothesis, it would be a parallel candidate for next-generation obesity care with a distinctive mechanism and dosing profile. The next 18 months are likely to clarify whether the deepest weight-loss agents of the late 2020s are GIP-agonist-based (retatrutide) or GIP-antagonist-based (MariTide) — a striking unresolved scientific question.